logo

Bioxcel Therapeutics, Inc. (BTAI)



Trade BTAI now with
  Date
  Headline
1/3/2019 8:25:27 AM BioXcel Therapeutics Reports Positive Human Proof-of-Concept Data For Acute Treatment Of Agitation; Stock Surges
12/27/2018 8:02:04 AM BioXcel Therapeutics Secures FDA Fast Track Designation For BXCL501 For Acute Treatment Of Agitation
12/19/2018 4:15:42 AM BioXcel Doses First Subjects In Pharmacokinetic And Safety Study Of BXCL501 For Acute Treatment Of Agitation
12/12/2018 4:01:00 AM BioXcel Announces FDA Acceptance Of IND For Lead Neuroscience Candidate, BXCL501 For The Acute Treatment Of Agitation
11/14/2018 4:03:21 AM BioXcel Therapeutics Says Positive Results From Phase 1b Study For IV Administered Dexmedetomidine
11/5/2018 4:00:39 AM BioXcel Therapeutics Announces FDA Acceptance Of IND For Lead Immuno-oncology Candidate, BXCL701
10/31/2018 4:05:46 AM BioXcel Therapeutics Says Presentation On Functional Immunological Memory Formation Across Diverse Tumor Types At SITC
10/30/2018 4:08:25 AM BioXcel Therapeutics Provides Update On Clinical Advancement Of BXCL501 For Acute Treatment Of Agitation
10/8/2018 7:03:19 AM BioXcel Therapeutics Announces Submission Of IND For BXCL701 In Treatment Emergent Neuroendocrine Prostate Cancer
9/24/2018 7:02:00 AM BioXcel Therapeutics Expands Immuno-Oncology Partnership With Nektar Into Clinical Development In Pancreatic Cancer
6/7/2018 8:18:26 AM BioXcel Therapeutics Appoints Vincent O’Neill As SVP And Chief Medical Officer
6/4/2018 8:34:28 AM BTI, Nektar Present Preclinical Pancreatic Cancer Data For BXCL701, NKTR-214 & Anti-PD1 Combination Therapy
5/14/2018 4:04:04 PM BioXcel Therapeutics Q1 Loss/share $0.37 Vs. Loss $0.06 Year Ago